Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
Genetic adjuvants enhance efficacy of vaccine against Her-2/neu tumor antigen
September 8th, 2004
Genetic adjuvants enhance the efficacy of DNA vaccination against Her-2/neu tumor antigen. According to published research from South Korea, "Certain types of malignant tumors overexpress Her-2/neu, a transmembrane glycoprotein of the class I receptor tyrosine kinase erbB family. To develop an effective Her-2/neu vaccine for selective immunotherapy of these malignancies, we prepared Her-2/neu DNA plasmid encoding the transmembrane and extracellular domain (pHM) and tested the ability of this construct to induce antitumor immunity in animal models. In addition, we investigated the effects of cytokine used as a genetic adjuvant." "Modulation by factors...
Source: Vaccine Weekly (2004-09-08)
|
